Healthcare Cost Reduction

Thyme Care Scales Serious Illness Program as 1 in 3 Members Qualify

Image
Thyme Care Scales Serious Illness Program as 1 in 3 Members Qualify

Nashville – November 05, 2026 -- Thyme Care is scaling its Serious Illness program after finding that one in three of its oncology members live with serious illness. For one national health plan partner, members connected to palliative care had 18% lower total spend in their final 30 days of life.

Inpatient savings account for 82% of the cost reduction at one national health plan partner

Inpatient spending drove 82% of the 18% reduction in end-of-life costs. Thyme Care attributes the savings to more appropriate care rather than less care.

AWV Completion Cuts Costs $70 PMPM for Florida ACO Network

Image
AWV Completion Cuts Costs $70 PMPM for Florida ACO Network

Dallas – October 07, 2026 -- Patients who completed Annual Wellness Visits through Primary Partners Alliance's (PPA) population health strategy generated nearly $70 lower per-member-per-month healthcare costs than those who did not, according to a one-year analysis of the organization's Medicare Shared Savings Program and ACO REACH population.

AWV completion drove measurable cost and utilization reductions across PPA's network

The analysis found per-member-per-month costs of $947 for patients who completed an AWV versus $1,014 for those who did not. Readmission rates were 44% lower among AWV completers, at 9% compared with 16% for non-completers. Emergency department utilization also fell, registering 272 visits per 1,000 patients versus 286 per 1,000 for the comparison group.

Rice-Backed Duracyte to Trial Implant That Makes Drugs Inside Body

Houston – October 02, 2026 -- Researchers at Rice University, backed by the Rice Biotech Launch Pad, have developed an implantable device that produced therapeutic monoclonal antibodies continuously for one year across multiple preclinical models, with the platform now advancing toward human trials through biotech company Duracyte.

Implant sustained antibody production for a full year in preclinical testing

The system, detailed in a study published in Science Advances titled "Once-yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies," uses engineered protein producers (EPPs) enclosed in a modified biomaterial. The retrievable device also let researchers halt treatment or adjust dosing by removing or replacing the implant, addressing the foreign body response -- inflammation and scar tissue buildup -- that typically limits implanted cell therapy performance.